Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 20 versus DYANAVEL XR 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 20 versus DYANAVEL XR 15.
ADDERALL XR 20 vs DYANAVEL XR 15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR 20 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine). It increases synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Dyanavel XR contains amphetamine, which is a central nervous system stimulant that increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
20 mg orally once daily in the morning.
1-3 capsules orally once daily in the morning. Each capsule contains 15 mg of amphetamine (equivalent to 15 mg dextroamphetamine/amphetamine).
None Documented
None Documented
Approximately 10-13 hours for d-amphetamine and 13-15 hours for l-amphetamine in adults; in children, 9-11 hours. The extended-release formulation provides a prolonged therapeutic effect masking shorter elimination.
Terminal elimination half-life: amphetamine (d-isomer) 9-11 hours, l-isomer 11-14 hours; allows for once-daily dosing in extended-release formulation
Approximately 90% of an oral dose is excreted renally, with 30% as unchanged amphetamine and the remainder as metabolites (including hippuric acid, benzoic acid, and hydroxylated derivatives). Fecal/biliary excretion accounts for <10%.
Renal (80-90% as unchanged drug and metabolites, primarily dehydro-amphetamine); fecal excretion minimal (<5%)
Category C
Category C
CNS Stimulant
CNS Stimulant